AstraZeneca | 6-K: Datopotamab Deruxtecan Biologics License Application Accepted in the Us for Patients with Previously Treated Metastatic HR-Positive, HER2-Negative Breast Cancer
AstraZeneca | 6-K: Datopotamab Deruxtecan Biologics License Application Accepted in the Us for Patients with Previously Treated Metastatic HR-Positive, HER2-Negative Breast Cancer
阿斯利康 | 6-K：Datopotamab deruxtecan Biologics許可申請在美國獲得批准用於治療既往接受過治療的轉移性HR陽性、HER2陰性乳腺癌患者
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。